BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 246 filers reported holding BIO-TECHNE CORP in Q1 2015. The put-call ratio across all filers is - and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $95,720,000 | -7.4% | 941,663 | -6.3% | 0.08% | -10.3% |
| Q4 2016 | $103,334,000 | -7.5% | 1,004,896 | -1.4% | 0.09% | -7.4% |
| Q3 2016 | $111,654,000 | +2.4% | 1,019,666 | +5.5% | 0.09% | +1.1% |
| Q2 2016 | $109,034,000 | -16.0% | 966,868 | -29.6% | 0.09% | -17.7% |
| Q1 2016 | $129,855,000 | -2.4% | 1,373,838 | -7.1% | 0.11% | 0.0% |
| Q4 2015 | $133,079,000 | -51.5% | 1,478,651 | -50.1% | 0.11% | -8.1% |
| Q3 2015 | $274,124,000 | +86.3% | 2,964,778 | +98.4% | 0.12% | +1.7% |
| Q2 2015 | $147,138,000 | -0.6% | 1,494,238 | +1.2% | 0.12% | -0.8% |
| Q1 2015 | $148,022,000 | +13.6% | 1,475,944 | +4.7% | 0.12% | +8.9% |
| Q4 2014 | $130,300,000 | – | 1,410,177 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brown Capital Management | 2,119,107 | $256,179,000 | 3.12% |
| STONE RUN CAPITAL, LLC | 42,925 | $5,189,000 | 2.67% |
| 440 INVESTMENT GROUP, LLC | 27,820 | $3,363,000 | 2.56% |
| Summit Creek Advisors LLC | 106,517 | $12,877,000 | 2.54% |
| MAIRS & POWER INC | 1,444,480 | $174,623,000 | 2.10% |
| QUANTUM CAPITAL MANAGEMENT | 57,094 | $6,902,000 | 1.63% |
| Select Equity Group, L.P. | 1,709,914 | $206,711,503,000 | 1.57% |
| FRIESS ASSOCIATES LLC | 144,610 | $17,482,000 | 1.53% |
| Tygh Capital Management, Inc. | 61,813 | $7,473,000 | 1.49% |
| First Light Asset Management, LLC | 38,654 | $4,673,000 | 1.48% |